It looks like you're using an Ad Blocker.
Please white-list or disable AboveTopSecret.com in your ad-blocking tool.
Some features of ATS will be disabled while you continue to use an ad-blocker.
Nontuberculous mycobacteria (NTM) are a heterogeneous group of organisms that occasionally are a primary cause of lung disease but more commonly affect patients with underlying chronic lung disease such as bronchiectasis, pneumoconiosis, or healed tuberculosis (1, 2). From an epidemiologic perspective, patients with cystic fibrosis (CF) are at high risk of NTM infection, but the clinical signs and symptoms of NTM are often difficult to distinguish from chronic bacterial pulmonary infections found in the advanced stages of CF.
Atypical mycobacteria are obligate aerobes that can be found in the environment in soil, water, vegetables, and even in domestic animals and dairy products.
Pharmaxis' key product in development, Bronchitol, is a drug designed to reduce the amount of mucus build-up in the lungs of patients suffering from chronic respiratory conditions. Pharmaxis is developing Bronchitol for diseases including cystic fibrosis, bronchiectasis and chronic bronchitis. Bronchitol is a proprietary formulation of mannitol administered as a dry powder in a convenient hand-held inhaler. Bronchitol hydrates the lungs, helps restore normal lung clearance, and allows patients to clear mucus more effectively. Clinical studies have shown Bronchitol to be safe, effective, and well tolerated in treating patients with both cystic fibrosis and bronchiectasis.
Lung damage caused by cystic fibrosis has been repaired by a cancer drug in a breakthrough that offers hope to tens of thousands. In tests, the drug, which was developed to treat blood cell cancers, reversed almost a third of the harm done to cells by CF. Read more: www.dailymail.co.uk...
Angelo DiStefano, 50, has struggled with the symptoms of cystic fibrosis his entire life. He was confined to a wheelchair and every breath was a challenge. DiStefano and his wife spent years researching a variety of treatments that could improve his condition. They discovered Zannos G. Grekos, MD, MAAC, FACC, chief medical officer of Regenocyte and a leading pioneer in the field of adult stem cell therapy, and worked with him to determine a new course of treatment With help from The Alliance for the Advancement of Adult Stem Cell Therapy and Research, DiStefano received his first Regenocyte adult stem cell treatment on May 4, 2011 in the Dominican Republic. Since only adult stem cells are used, the political, ethical and medical issues surrounding embryonic stem cells are avoided and there is no risk of rejection from the patient. In only a few months, his pulmonary function test (PFT) results show an increase in FEV1 from 18% to 32%, he is walking on his own, and he is able to leave the house to enjoy time with his wife.